GlaxoSmithKline (GSK) Offers Statement in Response to New York Times Article on China
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
GlaxoSmithKline (NYSE: GSK) said on its website:
These matters relating to our operations in China were deeply disappointing to GSK. They have previously been the subject of investigation by authorities in China and the United States. GSK cooperated fully with those investigations, which have since concluded and been resolved. GSK is committed to operating its commercial activities in an ethical and professional manner consistent with the Company’s values. Over the last few years, GSK has made significant changes to its commercial practices globally, which include changes to the way the Company’s sales representatives are compensated and stopping payments to Healthcare Practitioners to speak to other providers about its products.
More information on our business model changes is available here:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- Teva Pharma (TEVA) Loses Bid to Revive '413, '250, and Third Capaxone Patent in IPR Review - Bloomberg
- Allergan (AGN) Enters DELZICOL Patent Settlement Agreement
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!